JBIO · NASDAQ
Jade Biosciences (JBIO) Stock Price & Fundamentals
Jade Biosciences (JBIO) closed at $919.34 on Oct 9, 2026, down 0.99% from the previous close of $928.55.
Share price, past year
1Y +2.94%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $919.34 |
| Sep 30, 2026 | $915.21 |
| Aug 31, 2026 | $917.00 |
| Jul 31, 2026 | $891.23 |
| Jun 30, 2026 | $887.36 |
| May 29, 2026 | $960.06 |
| Apr 30, 2026 | $921.35 |
| Mar 31, 2026 | $907.81 |
| Feb 27, 2026 | $992.84 |
| Jan 30, 2026 | $953.09 |
| Dec 31, 2025 | $967.04 |
| Nov 28, 2025 | $1,023.90 |
| Oct 31, 2025 | $930.11 |
Key statistics
- Market cap
- $58.43B
- P/E (TTM)
- 108.9
- EPS (TTM)
- $8.44
- Net income (TTM)
- −$153.24M
- Shares outstanding
- 63.6M
- 52-week range
- $867.15 – $1,031.54
Jade Biosciences's market cap is $58.43B, based on a share price of $919.34 and 63.6M shares outstanding as of Jun 30, 2026.
Financials
Jade Biosciences's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Jade Biosciences reported a net loss of $127.41M in fiscal 2025.
Company profile
- Name
- Jade Biosciences, Inc.
- Ticker
- JBIO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001798749
Recent SEC filings
- Sep 30, 2026
- Aug 10, 2026
- Aug 10, 2026
- Jul 1, 2026
- Jun 26, 2026
- Jun 11, 2026
- Jun 4, 2026
- Jun 1, 2026
Frequently asked questions
What is Jade Biosciences's stock price?
Jade Biosciences (JBIO) closed at $919.34 on Oct 9, 2026, down 0.99% from the previous close of $928.55.
What is Jade Biosciences's market cap?
Jade Biosciences's market cap is $58.43B, based on a share price of $919.34 and 63.6M shares outstanding as of Jun 30, 2026.
What is JBIO's P/E ratio?
Jade Biosciences's price-to-earnings ratio is 108.9, based on trailing twelve-month diluted EPS of $8.44.
Does Jade Biosciences pay a dividend?
Jade Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Jade Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures